i just answered a ? via PM from someone trying to understand the use of the word *over* in regards to the $24 million noted

to me it's clear the *over* in the quote below pertains to the initial upfront payment
which is not defined .. imo deliberately so .. as i've noted a few times .. we all
come at this from varying perspectives .. and to me it makes total sense that that
payment would not be noted at this point in time by IP

Quote:

---

The Company will receive from Alfasigma an initial payment, plus be eligible for additional payments based on certain milestones, totaling over $24 million , and receive a 6 percent royalty (net sales) based on the successful marketing of Brilacidin for UP/UPS. The agreement also includes a Right of First Refusal for Brilacidin for the treatment of more extensive forms of Inflammatory Bowel Disease (IBD), such as Ulcerative Colitis and Crohn’s Disease, and a Right of First Negotiation for Brilacidin in other Gastrointestinal indications.

---

Read More: https://investorshangout.com/post/view?id=549...z5uYdoWbS8

4kids

"The partnership provides us access to initial and milestone-based capital" -- from Mr. Ehrlich's letter to shareholders.

What could be more clear than AND?

I know the liars want to say that the initial payment is part of the 24 million, but it isn't.

Read More: https://investorshangout.com/post/newpost/873...z5uYfSFmjk